Hypertension Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with a condition requiring a dual-chamber pacemaker, or who are already planning to receive one — specifically a Medtronic Astra/Azure model
- People who are currently on a stable medication routine to manage high blood pressure, including at least one blood pressure-lowering drug
- People whose blood pressure reading taken at a clinic is 135 mmHg or higher, but below 180 mmHg (the top/systolic number)
- People whose average blood pressure measured over a 24-hour monitoring period is 130 mmHg or higher, but below 170 mmHg (the top/systolic number)
Who may not be able to join:
- People whose heart's pumping strength (ejection fraction) is below 50%
- People with moderate-to-severe heart failure symptoms, classified as NYHA Class III or IV (confirm with trial site)
- People who have had a stroke or mini-stroke (TIA) within the past 6 months
- People who have had a heart attack within the past 3 months
- People who have undergone a heart, carotid artery, or blood vessel procedure (either by keyhole or open surgery) within the past 3 months
- People with permanent atrial fibrillation (a long-term irregular heart rhythm)
- People with significant leaking of the mitral heart valve, graded 3 or higher
- People with a narrowed aortic heart valve where the opening is smaller than 1.5 cm²
- People who have previously had, or currently have, a device-based treatment for high blood pressure (such as a kidney nerve procedure or a nerve-stimulation therapy)
- People who already have another active implanted heart device or nerve stimulator, separate from the Astra/Azure pacemaker being used in this trial
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: David Kandzari, MD, Piedmont Heart Institute
Phone: 646-956-2161
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
1 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Change from Baseline in the Mean 24-hour ambulatory systolic blood pressure (aSBP) at 3 Months; Freedom from Unanticipated Serious Adverse Device Effects (USADE)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.